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Previousreportsshowineﬀectivetransdermaldeliveryofketorolacbynanostructuredlipidcarriers(NLCs).Theaimofthepresent
work was enhancement of transdermal delivery of ketorolac by another colloidal carriers, lipid nanocapsules (LNCs). LNCs were
prepared by emulsiﬁcation with phase transition method and mixed in a Carbomer 934P gel base with oleic acid or propylene
glycol as penetration enhancers. Permeation studies were performed by Franz diﬀusion cell using excised rat abdominal skin.
Aerosil-induced rat paw edema model was used to investigate the in vivo performance. LNCs containing polyethylene glycol
hydroxyl stearate, lecithin in Labrafac as the oily phase, and dilution of the primary emulsion with 3.5-fold volume of cold water
produced the optimized nanoparticles. The 1% Carbomer gel base containing 10% oleic acid loaded with nanoparticles enhanced
and prolonged the anti-inﬂammatory eﬀects of this drug to more than 12h in Aerosil-induced rat paw edema model.
1.Introduction
Lipid nanocapsules (LNCs) are a new generation of biomi-
metic nanovectors composed of an oily core of medium-
chain triglycerides of capric and caprylic acids known under
the commercial name of Labrafac that is surrounded by a
shell composed of lecithin and a pegylated surfactant called
Solutol HS 15. Solutol is a mixture of free PEG 660 and
PEG 660 hydroxystearate and oriented towards the water
phase. Lecithin is composed of 69% phosphatidylcholine
soya bean and is generally used in small proportions to
signiﬁcantly increase LNC stability [1, 2]. Their structure
mimics lipoproteins [3, 4] while have a hybrid structure
betweenpolymernanocapsulesandliposomes.LNCspresent
a great physical stability up to 18 months with size ranges
from 20 to 100nm. They are prepared by a phase inversion
of an oil/water emulsion due to thermal manipulation and in
the absence of organic solvents with good monodispersion
[5]. The aqueous phase consists of MilliQ water plus sodium
chloride salt, which helps to decrease the phase-inversion
temperature (PIT) [5, 6].
Preparation of LNCs involves two steps. In the ﬁrst step
all mixed components are heated from room temperature up
to T2 temperature, above the PIT, to obtain a W/O emulsion.
Then the temperature is dropped to T1 below the PIT, by
a cooling process that leads to the formation of an O/W
emulsion. After several temperature cycles between T2 and
T1 the temperature is set 1–3◦C lower from the beginning
of the O/W emulsion before dilution. At the second step by
a sudden dilution with cold water added to the mixture an
irreversible shock causes to break the microemulsion system,
and stable nanocapsules are formed [7]. Three temperature
cycles of heating and cooling at the rate of 4◦C/min are
usually applied between 85 and 60◦C[ 5, 8].
They have been used from diﬀerent routes of adminis-
tration including oral [9, 10], parenteral, and transdermal
routes [11–13]. Improved bioavailability, increased drug tar-
geting, achieving controlled drug release [14–16], increasing2 Journal of Drug Delivery
thestabilityoftheentrappeddrugs,lowbiotoxicity,andgood
biocompatibility are some advantages reported for LNCs
[17].
The gastrointestinal side eﬀects of nonsteroidal anti-
inﬂammatory drugs (NSAIDs) have limited their widely
oral use as analgesics in the treatment of local inﬂam-
mation. This has prompted researchers to investigate the
feasibility of alternative dermal and/or transdermal drug
delivery systems. Ketorolac is a pyrrolizine carboxylic acid
derivative of NSAIDs with potent analgesic and moderate
anti-inﬂammatory activity, a relatively favorable therapeutic
agent for the management of moderate to severe pain [18].
Ketorolac tromethamine is administered intramuscularly
and orally in divided multiple doses for short-term manage-
ment of postoperative pain. Its oral bioavailability is 90%
with a very low ﬁrst pass metabolism. However, the drug
is reported to cause severe gastrointestinal side eﬀects such
as gastrointestinal bleeding, perforation, peptic ulceration,
and acute renal failure [19]. Because of the short half-life (4
to 6h) of ketorolac, frequent dosing is required to alleviate
pain. To avoid intramuscular injection and frequent dosing
regimens, dermal and transdermal delivery of ketorolac is
an attractive alternative. Additionally, high analgesic activity
and low molecular weight of ketorolac make it a good
candidate for transdermal delivery. Several transdermal
delivery strategies such as use of permeation enhancers
[20], proniosomes [21], its prodrugs [22], iontophoresis
[23], ultrasound [24], cyclodextrins and liposomes [25],
and nanostructured lipid carriers (NLCs) [26]h a v eb e e n
developed so far. NLCs are mixtures of solid and liquid lipids
(oils) which provide greater solubility for drugs than solid
lipids. These nanostructures of ketorolac were ineﬀective in
increasing the drug percutaneous absorption due to the high
degree of mutual interaction between the drug and carrier
lipid matrix. For this reason we propose another colloidal
lipid nanocarrier, that is, LNCs for transdermal delivery of
ketorolac due to their high content of hydrophilic surfactants
which may improve the problem of previous nanoparticles
of this drug and reduce high degree of interactions between
the drug and nanoparticles. The LNCs are prepared by an
emulsiﬁcation-phase conversion process with 10–40% or
more of surfactants and contain no organic solvent.
2.MaterialsandMethods
2.1. Materials. Ketorolac tromethamine (MSN Laboratory,
India), Labrafac (capric and caprylic acid triglyceride) and
polyethylene glycol hydroxyl stearate (Solutol HS15) were
kindly provided by BASF (The Chemical Company, Lud-
wigshafen, Germany), Carbomer P934 (BF Goodrich, US),
soy lecithin S100 (Lipoid, Germany), Aerosil (Fluka, US),
triethanolamine (Sigma, US), oleic acid, propylene glycol,
Tween 20 and all other reagents were from Merck, Chemical
Company(Germany).Ketamine10%vialwasfrom(Alfasan,
Netherland).
2.2. Preparation and Optimization of LNCs Using Taguchi
Design. Table 1 displays the four control factors that were
selected in the optimization study. A standard orthogonal
Table 1: Diﬀerent variables and their levels studied by Taguchi
design for production of nano lipid capsules of ketorolac trome-
thamine.
Variable Level
II II I I
Surfactant % (S) 20 25 30
Oil phase % (O) 10 17.5 25
Volume of diluting aqueous phase ml (W) 1.2 2.35 3.5
Lecithin % (L) 1.5 2.35 3.25
array L9 [27] was used to examine this four-factor system.
L and subscript 9 denote the Latin square and the number
of the experimental runs, respectively. A run involved the
corresponding combination of levels to which the factors in
the experiment were set. All studied factors had three levels.
All experiments were performed in triplicate.
Four studied responses included particle size, zeta poten-
tial, loading eﬃciency, and drug release eﬃciency percent
until 65min (RE65%). The experimental results were then
analyzed by the Design Expert software (version 7, USA)
to extract independently the main eﬀects of these factors,
followed by the analysis of variance (ANOVA) to determine
which factors were statistically signiﬁcant. Identifying con-
trolling factors and qualifying the magnitude of eﬀects, as
well as identifying the statistically signiﬁcant eﬀects, were
emphasized. The optimum conditions were determined by
theTaguchi’soptimizationmethod[28]toyieldaheightened
performance with the lowest possible eﬀect of the noise
factor.
To prepare the LNCs 400mg drug was dissolved in
2.73mLofaqueousphasecontaining1.75%NaCl(according
to the aqueous phase) and diﬀerent amounts of polyethylene
glycol hydroxyl stearate as the surfactant (according to
Table 1). The oily phase was Labrafac which contained
lecithin as the stabilizing agent. The amount of each variable
is shown in Table 1. The two phases were added to each
other on a magnetic stirrer, and the mixture temperature
was raised from room temperature to 85◦C gradually during
15min.Thenitwascooledto25◦C.Three temperaturecycles
(85–60–85–60–85◦C) were applied to reach the inversion
process. The temperature of the mixture before dilution was
set 57◦C, in the o/w emulsion. Step II was an irreversible
shock induced by dilution (1.2–3.5 times) with cold de-
ionised water (0◦C) added to the mixture maintained
at the previously deﬁned temperature. This fast-cooling
dilution process led to the formation of stable nanocapsules.
Afterwards slow magnetic stirring for 5min was applied to
the suspension [7].
2.3. Particle Size and Zeta Potential of the LNCs. Size and
zetapotentialofalldrug-loadedLNCsamplesweremeasured
by photon correlation spectroscopy (PCS, Zetasizer 3000,
Malvern, UK). All the samples were diluted one to ten ratio
with deionized water to get optimum 50–200 kilo counts
per second (Kcps) for measurements. Intensity Z-Average
particle size, polydispersity index, and zeta potential were
measured.Journal of Drug Delivery 3
2.4. Morphology Study. Morphology of the LNCs was char-
acterized by scanning electron microscopy (SEM). The
nanoparticles were mounted on aluminum stubs, sputter
coated with a thin layer of Au/Pd, and examined using an
SEM (Seron Technology 2008, Korea).
2.5. Drug Loading Eﬃciency in LNCs. Entrapment eﬃciency
percent (EE%) was determined by measuring the concentra-
tion of unentrapped free drug in aqueous medium [29]. The
aqueous medium was separated by centrifugation (Sigma
3K30, Germany). About 0.5mL of the LNC dispersion was
placed in the eppendorf Amicon Ultra centrifugal ﬁlters with
cut-oﬀ10KDaandcentrifugedat15000rpmfor10min.The
encapsulated drug in nanoparticles was separated, and the
amount of free ketorolac in the aqueous phase was estimated
by UV spectroscopy method at λmax = 319.3nm. The EE%
and loading percentage were calculated using:
EE (%)
=

Analyzes weight of drug in LNC
Theoretical weight of drug loaded in system

×100,
Loading %
=

Analyzed weight of drug in LNC
Analyzed weight of LNC

× 100.
(1)
2.6. Drug Release Studies from LNCs. To determine the
release rate of ketorolac from nanoparticles 1mL of aqueous
dispersion of each formulation was added to the dialysis bags
with molecular weight cutoﬀ of 12400Da, and the sealed
bags were placed in the glass test tube in 25mL of the
phosphate buﬀer solution (PBS) 0.1M (pH 7.4) to provide
sink conditions with agitation of 200rpm on magnetic
stirrer. Samples were withdrawn at 15min time intervals up
to 65min and replaced with fresh PBS maintained at the
same temperature. The content of ketorolac in the samples
was determined spectrophotometrically at λmax = 323nm.
2.7. Preparation and Optimization of LNC-Based Gels Using
Factorial Design. Three diﬀerent variables each in 2 levels
were evaluated for preparation of the gel bases (Table 2).
The gel formulations were prepared using a 2-level factorial
design. Carbomer was dispersed in water using an overhead
stirrer at a speed of 600rpm for 3hr. Carbomer gels were
diluted to ﬁnal concentration of 0.5–1% with the optimized
formulation of LNCs and then neutralized using 0.5w/w%
triethanolamine. Then one of the absorption enhancers
(oleic acid or propylene glycol) was added at diﬀerent
concentrations (Table 2).
2.8. Skin Permeation through Excised Hairless Rat. In vitro
permeation of ketorolac from various gel formulations was
evaluated using full thickness abdominal skin excised from
adult Wistar rats weighing 150–180g. The visceral side of
the freshly excised skin was cleaned free of any adhering
Table 2: Diﬀerent variables and their levels studied by 2-level
factorial design for production of gels of nano lipid capsules of
ketorolac tromethamine.
Variable Level
II I
Enhancer type Oleic acid (O) Propylene glycol (P)
Enhancer % 10 15
Carbomer concentration 0.5 1
subcutaneous tissue. The hair on the epidermal surface of
the skin was cut, and the skin was hydrated for 24h in PBS
(pH7.4).Theskinsamplesw e r emount edo nF ranzdiﬀusion
cells with a diameter of 2.6cm and a receptor volume of
28mL such that the dermal side of the skin was exposed
to the receptor ﬂuid and the stratum corneum remained
in contact with the donor compartment. PBS (pH 7.4) was
ﬁlled in the receptor compartment and stirred continuously
with the help of a magnetic stirrer. The receptor medium
was water jacketed at 37◦C. On the epidermal side of the
skin, 1g of the gel was spread evenly. Two mL samples
were withdrawn from receptor medium and replaced with
f r e s hm e d i u ma t0 . 5 ,1 ,2 ,4 ,1 6 ,a n d1 7 h .S a m p l e sw e r e
analyzed spectrophotometrically for the content of ketorolac
at 323nm. Blank formulations (without drug) were used
as a reference for the determination of ketorolac to negate
any possible interference from the skin components or
formulation components. Cumulative amount of drug (Q)
permeatedthroughskinwasplotted asafunctionoftime(t).
The drug concentration in the donor cell (Cd) and its surface
area (S) were used for calculation of the permeability (P):
Q = PSCdt. (2)
Flux (Js) was calculated from (3) in which (dQ/dt) is the
amount of drug ﬂowing through a unit cross-section (S)o f
the skin in unit time (t)
JS =
1
S
dQ
dt
. (3)
To obtain the diﬀusion coeﬃcient (D) of the drug through
the skin (4)w a su s e d :
tL =
h2
6D
,( 4 )
In which (tL) is the lag time of drug permeation and (h)i s
the thickness of the rat skin. Finally the partition coeﬃcient
(Km) of drug between skin and vehicle was obtained from:
Km =
P · D
h
. (5)
All the experiments were performed in triplicate. After
optimization of the gel formulation according to the highest
skin permeability, the optimized gel was applied for in vivo
studies in alleviating the Aerosil-induced paw edema in rat.4 Journal of Drug Delivery
Table 3: Physical properties of nano lipid capsules of ketorolac tromethamine (RE65% is released eﬃciency percent of drug until 65min of
release test) (results are mean ± SD).
Type of nanoparticles Average size (nm) Zeta potential (mV) Drug loading eﬃciency (%) RE65 (%)
S25O10W2.35L5 56.0 ±24.9 −3.3 ±0.73 8 .6 ±2.54 4 .4 ±1.7
S20O10W1.2L1.5 59.7 ±11.4 −1.6 ±0.41 3 .5 ±0.44 0 .6 ±3.4
S30O10W3.5L3.25 20.5 ±0.7 −3.7 ±0.33 6 .2 ±3.14 3 .2 ±1.5
S25O25W1.2L3.25 221.0 ±42.2 −1.9 ±0.12 8 .9 ±0.42 5 .0 ±0.2
S30O17.5W1.2L5 39.5 ±8.2 −1.8 ±0.13 4 .0 ±0.72 4 .4 ±0.0
S25O17.5W3.5L1.5 86.8 ±2.2 −3.9 ±0.42 3 .0 ±1.53 8 .6 ±0.0
S30O25W2.35L1.5 196.2 ±4.5 −3.3 ±0.62 9 .8 ±2.52 6 .7 ±0.0
S20O25W3.5L5 54.8 ±4.24 .0 ±0.62 6 .6 ±1.23 9 .5 ±0.4
S20O17.5W2.35L3.25 60.5 ±12.8 −4.2 ±0.43 4 .8 ±6.83 9 .1 ±0.3
Optimized LNCs (S20O25W3.5L3.25) 102.7 ±0.8 −7.8 ±0.53 1 .0 ±10.63 7 .4 ±1.3
2.9. In Vivo Studies
2.9.1. Animals. 36 male albino Wistar rats with body weight
of 150–180g (70–90 days aged) were selected for all the
experiments. Animals were kept in the animal house at 23–
30◦C and 45–55% relative humidity. The Isfahan University
of Medical Sciences ethical committee approved all animal
experiments in the present study.
2.9.2. Aerosil-Induced Paw Edema in Rats. Male Wistar
rats were studied into 6 groups of six rats, each group
receivingadiﬀerenttopicaltreatment.0.1mLof2.5%Aerosil
suspension in distilled water was injected in the right hind
foot of each rat. Immediately after injection of Aerosil the
rats of the test groups were administered the developed
optimized LNC-based gels containing 0.5 or 2% ketorolac,
the 2 standard groups were treated with the traditional gels
of 0.5 or 2% free ketorolac in the same gel base as LNCs,
the control group received no treatment, and another group
received the blank vehicle.
Measurement of the foot volume was performed by the
displacement technique using plethysmograph (Ugo Basile,
Italy) immediately before and 2, 4, 8, 12, and 24h after the
injection of Aerosil. Edema inhibition rate (I)a f t e rd i ﬀerent
treatments was calculated using:
E =
Vt −Vo
Vo
,
I% =
Ec −Et
Ec
×100,
(6)
where Vo is the mean paw volume before Aerosil injection,
Vt is the mean paw volume after Aerosil injection, Ec is the
edema rate of the control group, and Et is the edema rate of
the treated group [30].
2.10. Statistical Analysis. SPSS software version 11.5 was
used for all statistical analysis. One-way analysis of variance
(ANOVA) followed by a Tukey’s post hoc test was used for
comparison between cumulative percentage of drug released
at the end of each release test.
In vivo data were expressed as mean ± SD. Diﬀerences
between mean values were analyzed using one-way analysis
of variance (ANOVA) followed by a Dunnett’s post hoc. A
signiﬁcant level of P<0.05 denoted signiﬁcance in all cases.
3. Results and Discussion
Diﬀerent formulations of ketorolac LNCs were prepared
accordingtoTable 3 andwerecharacterizedfortheirphysical
properties including particle size, surface charge (zeta poten-
tial), drug loading eﬃciency percent, and release eﬃciency
until 65min of release test (RE65%). The results are shown in
Table 3. Optimization was performed to obtain the optimal
pointsregardingtheconstraintsinwhichtheparticlesizewas
in its minimum level, the absolute value of zeta potential
in its maximum level, while release eﬃciency percent and
loading eﬃciency percent were in their range levels (Table 3).
The optimized formulation of LNCs was predicted by
Design Expert software to contain 20% polyethylene glycol
hydroxyl stearate (coded as level I), 25% Labrafac, 3.25%
lecithin, and diluting cool water 3.5-fold of the volume of
the primary emulsion (all coded as level III in Table 1).
The optimized formulation of LNCs was prepared and
characterized for their physical properties (Table 3). The
nanoparticulate natureof theLNC dispersion wasconﬁrmed
by SEM studies (Figure 1), otherwise some aggregation of
nanoparticles is obvious. The morphology of this optimized
LNC formulation is seen in Figure 1.
Drug release proﬁles through LNC formulations are
compared with the optimized formulation in Figure 2.A s
this ﬁgure shows most of the studied LNCs release about
70% of the loaded drug within 65 minutes with a zero order
or Baker-Lonsdale kinetics model indicating the particulate
nature of the LNCs.
Statistical analysis of the release eﬃciency (RE65%) of
diﬀerent formulations of LNCs by Design Expert software
shows that increasing amounts of Solutol and Labrafac
decreases the RE65%, but increasing the cold water volume
during dilution step increases the RE65%. Lecithin amount
has not signiﬁcant eﬀect on RE65%.Journal of Drug Delivery 5
IAU-Majlesi Branch SEI WD = 10.5 20.00kV 500nm
67.6nm
132.14nm
64.53nm
×60K
IAU-Majlesi Branch SEI WD = 10.5 20.00kV 500nm ×60K
Figure 1: SEM micrographs of optimized formulation of Ketorolac
loaded lipid nanocapsules (S20O25W3.5L3.25).
0
10
20
30
40
50
60
70
80
90
0 10 20 30 40 50 60 70
Time (min)
k
e
t
o
r
o
l
a
c
 
r
e
l
e
a
s
e
d
 
(
%
)
Optimized
S25O10W2.35L5
S20O10W2.35L1.5
S30O10W3.5L3.25
S25O25W1.2L3.25
S30O17.5W1.2L5
S25O17.5W3.5L1.5
S30O25W2.35L1.5
S20O25W3.5L3.25
S20O17.5W2.35L3.25
(S20O25W3.5L3.25)
Figure 2: Ketorolac release proﬁle from lipid nanocapsules with
diﬀerent formulations.
Considering the high solubility of the drug in both water
and organic solvents and as there is not any burst eﬀect
in the release proﬁles (Figure 3) it seems that the drug is
accommodated in the core of the matrix of LNCs.
To optimize the gel base for loading LNCs, the Carbomer
gels were loaded with the optimized LNC formulation,
and permeability of drug through the excised hairless skin
of rat was measured. Diﬀerent formulation of gel bases
were designed by an irregular 2-level factorial design and 3
variableseachin2levelswerestudied(Table 2).Theresultsof
measurements of permeability, ﬂux, and partition coeﬃcient
of drug between skin and vehicle are seen in Table 4.
As shown in Table 4, skin permeation was signiﬁcantly
enhanced by gel of O10C1. Oleic acid possesses skin
penetration enhancing ability. Considering skin structure,
water solubility is an important parameter that drastically
inﬂuences drug permeation proﬁle. The skin is composed of
a comparatively lipophilic stratum corneum and hydrophilic
viableepidermisanddermis.Onthebasisofthepermeability
results, O10C1 gel containing LNCs of ketorolac showed an
optimal balance between lipophilicity and hydrophilicity.
This behaviour could be explained by balancing the high
percentage of polyethylene glycol hydroxyl stearate (Solutol),
the hydrophilic surfactant used in the LNCs, and lipophilic
oleic acid used in preparing the gel base. Comparing the
results of Table 4 for the optimized gel containing LNCs of
ketorolac with the traditional gel of free ketorolac indicates
13 fold increase in permeability for the gel-based LNCs. This
indicates a signiﬁcant increase in permeability and ﬂux of
ketorolac when encapsulated in the LNCs indicating a much
better aﬃnity of drug to the stratum corneum. On the other
hand, Table 4 shows that Km value for the gel-based LNCs
has a much higher value than what is reported for NLC of
this drug by Puglia et al. [26]. Generally a high Km value
indicatesthatthevehiclehasapooraﬃnityforthedruganda
low Km value, indicating a high degree of mutual interaction
and the tendency of drug to remain in the vehicle [26].
This shows the LNCs have lower interaction with ketorolac
tromethamine than NLCs due to higher hydrophilicity of
Solutol used in their formulation. Therefore, the vehicle
could not sequester the drug, and the drug is available for
diﬀusion while in other gel formulations this balance is not
produced well and skin permeation of the drug is drastically
less (Table 4). The optimized gel formulation was considered
to contain 1% Carbomer and 10% of oleic acid. This gel was
applied for in vivo evaluation in controlling the oedema in
paw of rat after Aerosil injection. Figure 3 depicts the results
of inhibition percent of inﬂammation after application of
free ketorolac 0.5 and 2% in gel base as a conventional gel
and the drug encapsulated in LNCs compared to the vehicle
a n dc o n t r o lg r o u po fr a t s .
As this ﬁgure shows, conventional and LNC gels contain-
ing 0.5% of ketorolac had signiﬁcant diﬀerence (P<0.05)
with the control and vehicle group in reducing the edema
in paw of rats at all time point of the study except at 24hr.
In these gels the maximum inhibition% in edema happened
at 4h. However, the eﬀect of LNC gels containing 0.5% of
ketorolac continued until 8 hr so that the area under the
inhibition% time curve (AUC0–24) was signiﬁcantly greater6 Journal of Drug Delivery
Table 4: Permeability of ketorolac tromethamine loaded in optimized nano lipid capsules through hairless rat skins from diﬀerent gel
vehicles compared with free drug loaded in gel of O10C1 (results are mean ± SD).
Composition of gel vehicle Permeability ×106 (cm/sec) Flux (μg/cm2sec) Km
Free drug in O10C1 gel 0.6 ±0.03 0.0006
O10C1 8.3 ±0.6 0.009 74.7
O10C0.5 4.2 ±0.4 0.005 26. 5
P10C1 2.1 ±0.2 0.002 5.3
O15C1 3.0 ±0.6 0.003 12.6
P15C1 2.5 ±0.4 0.003 7.87
P10C0.5 2.6 ±0.1 0.003 6.68
P15C0.5 1.0 ±0.1 0.001 0.25
O15C0.5 3.7 ±0.2 0.004 24.53
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Figure 3: Anti-inﬂammatory activity (Inhibition %) of ketorolac
on paw edema induced with Aerosil injection (0.1mL of 2.5%w/w)
in rats (control), after administration of transdermal gels of
optimized ketorolac LNC (0.5% and 2%), the vehicle, and the gel
containing 0.5 or 2% of free ketorolac. The formulation of the gels
of ketorolac LNC contained (1% Carbomer gel base containing
10% oleic acid and 2% ketorolac loaded in optimized LNCs
(S20O25W3.5L3.25) prepared by 20% polyethylene glycol hydroxyl
stearate, 3.25% lecithin, 25% Labrafac as the oily phase, and cold
water as much as 3.5-folds of the total volume of the primary
emulsion).
for 0.5% optimized LNC than 0.5% gel (P<0.05) (Table 5).
After 12hr the inhibition% declined for both 0.5% gel and
LNC. The anti-inﬂammatory eﬀect of both 2% LNC and
conventional 2% ketorolac gels lasted for more than 12hr
after drug administration. The diﬀerence between AUC0–24
gels with other groups was signiﬁcant (P<0.05), and the
diﬀerence between 2% LNC and 2% gel was also signiﬁcant
(P<0.05) (Table 5).
This means that their eﬀect lasts more than other treat-
ments. The high activity of the 2% gel could be attributed to
the presence of a high amount of oleic acid, a known skin-
penetration enhancer in the vehicle of LNCs. However, the
Table 5: Area under the curve of inhibition time after adminis-
tration of ketorolac tromethamine loaded in optimized nano lipid
capsules from diﬀerent gel vehicles after induction of inﬂammation
in rat paws by Aerosil injection (results are mean ± SD).
Treatment groups AUC2–24 (%.h)
LNC 2% 510.59 ±7.00
gel %2 488.59 ±4.86
LNC 0.5% 152.59 ±5.4
gel 0.5% 119.87 ±5.89
Vehicle 11.01 ±4.86
No treatment 0.00 ±0.00
sustained activity of the LNC-based gel even at the end of
12h could be explained by the drug encapsulated within the
LNCs, while the fast onset is explained by the free drug in the
outer phase of dispersion. Abdel-Mottaleb et al. [31] studies
showed that LNCs caused higher permeation-enhancing
eﬀect compared to polymeric nanoparticles, while they had
similarpermeationtosolidlipidnanoparticles(SLN).Onthe
other hand, LNCs had the advantage of lower intradermal
drug accumulation as well as higher loading eﬃciency
combined with less stability problems compared to SLN.
4. Conclusion
Unlike the NLCs of ketorolac reported before that could not
enhance transdermal anti-inﬂammatory eﬀects of this drug,
the LNCs reported in this paper showed 13-fold increases
in permeability of ketorolac compared to conventional gels.
The partition coeﬃcient of drug between stratum corneum
and the vehicle was signiﬁcantly higher than what is reported
for NLCs of this drug. The results of inhibition percent of
inﬂammation induced by Aerosil in the paw of the rats also
allow to conclude that encapsulation of ketorolac in LNC-
based gel can enhance and prolong the anti-inﬂammatory
eﬀects of this drug for more than 12h.
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